CeriBell Corp (CBLL) - Kapitalizatsiyaning foydaga nisbati
CeriBell, Inc. (CBLL) aksiyalarining narxlar tarixi AI EEG monitorlari uchun SaaS modelining samaradorligini baholashga yordam beradi, bu esa barqaror pul oqimi va yuqori daromadlilikni ta'minlaydi. Joriy ko'rsatkich -14.70 ni tashkil etadi. Ijobiy dinamika portativ tizimlar ishlab chiqarishning rejalashtirilgan kengayishi va sexlarning modernizatsiyasi bilan qo'llab-quvvatlanmoqda. Biroq, eksport cheklovlari va yarimotkazgichlar yetishmasligi brendning yangi bozorlarga kirib borishiga to'sqinlik qilmoqda va servis xizmatlarini sekinlashtirmoqda.
CeriBell Corp (CBLL) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning xususiy kapitalga nisbati CeriBell, Inc.|CBLL - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati CeriBell EEG|CBLL - Kompaniya qarzlari|Qarzning balans kapitallashuviga nisbati CeriBell, Inc.|CBLL - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzi CeriBell|Oraliq qoplash koeffitsiyenti ceribell.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
CBLL - Sof foyda|Kompaniya foydasi prognozi CeriBell, Inc.|CBLL - Narxning foydaga nisbati|Narxning kelajakdagi foydaga nisbati CeriBell Inc|CBLL - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti CeriBell, Inc.|CBLL - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda CeriBell|CBLL - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi ceribell.com|CBLL - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun sof foyda o'sishi prognozi CeriBell, Inc.
Kompaniyaning har tomonlama tahlili:ceribell.com
CeriBell, Inc. (CBLL) kompaniyasining EEG tizimlarini kengaytirish uchun inson kapitaliga kiritgan investitsiyalari sof foydaga bevosita ta'sir ko'rsatib, ushbu koeffitsiyentning maxrajini shakllantiradi. Ushbu ko'rsatkich joriy bozor kapitalizatsiyasini yillik daromadlar bilan bog'lab, bir dollar foydaning tannarxini va biznesning yetuklik darajasini belgilaydi. Ushbu koeffitsiyentning barqarorligi aktivning defensiv xususiyatlarini tasdiqlab, spekulyativ shovqinlarni filtrlaydi. P/E baholash tahlili R&D investitsiyalarining haqiqiy rentabelligini aniqlash imkonini beradi.
Raqobatdosh kompaniyalar tahlili
Narx-foyda koeffitsiyenti biogen.com (BIIB)|P/E multiplikatori NBIX|RGC - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Axsome Therapeutics Inc AXSM|Kompaniya qiymatining sof foydaga nisbati ACAD|Xenon Pharmaceuticals - P/E multiplikatori|Biznesning o‘zini qoplash muddati vikingtherapeutics.com VKTX|SUPN: P/E multiplikatori|CPRX (Catalyst Pharma) - Narxning foydaga nisbati|DNLI (Denali Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Harmony Corp HRMY|Narxning foydaga nisbati Biohaven Ltd. (BHVN)|Narxning foydaga nisbati AMLX (amylyx.com)|Narxning foydaga nisbati Trevi Therapeutics, Inc. TRVI|Praxis Precision Medicines Inc - Narxning foydaga nisbati|AVXL: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati PRTA (Prothena Corporation)|ALEC: P/E multiplikatori|ANNX - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Omeros Corp|Narx-foyda multiplikatori NGNE (Neurogene Inc)|P/E multiplikatori ACIU|Narx-foyda koeffitsiyenti Voyager Corp VYGR|Neumora Therapeutics - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati scilexholding.com (SCLX)|Tevogen Bio - P/E multiplikatori|Alpha Cognition (ACOG) - Narx-foyda koeffitsiyenti|CGTX: P/E multiplikatori|IKT (Inhibikase Pharma) - Narxning foydaga nisbati|Narxning foydaga nisbati Cassava Sciences, Inc.|Narxning foydaga nisbati ASRT|Narxning foydaga nisbati Coya Therapeutics, Inc. (COYA)|Narxning foydaga nisbati VTGN (vistagen.com)|Narxning foydaga nisbati Ovid Therapeutics OVID|ABOS: Narx-foyda multiplikatori|CervoMed Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Alterity Therapeutics|CLNN (clene.com) - Narx-foyda koeffitsiyenti|PepGen (PEPG) - P/E multiplikatori|Narxning foydaga nisbati Jupiter Neurosciences|RLMD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|GRCE - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori AIFF (Firefly Neuroscience)|KLTO - Narx-foyda koeffitsiyenti|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Reviva Pharmaceuticals, Inc.|metaviatx.com (MTVA) - Narxning foydaga nisbati|neuraxis.com - Kompaniya qiymatining sof foydaga nisbati|HSDT (Helius Medical Technologies, Inc.) - P/E multiplikatori|Passage Bio Corp (PASG) - Biznesning o‘zini qoplash muddati|P/E multiplikatori NEUP|Narxning foydaga nisbati NERV (Minerva)|P/E multiplikatori ATHA (Athira Pharma, Inc.)|addextherapeutics.com (ADXN) - Kapitalizatsiyaning foydaga nisbati|ALZN - Narxning foydaga nisbati|CYCN: Narxning foydaga nisbati|protagenic.com (PTIX) - Narxning foydaga nisbati|KTTA (Pasithea Therapeutics Corp.) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti CRGT|ATXI: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori BCLI|Biznesning o‘zini qoplash muddati Cara Therapeutics Inc.|Narxning foydaga nisbati Chromocell Therapeutics Corporation CHRO|ELYM: Narx-foyda multiplikatori|Intra-Cellular - P/E multiplikatori|longboardpharma.com (LBPH) - Narx-foyda koeffitsiyenti|MRNS (Marinus Pharmaceuticals, Inc.) - Narx-foyda koeffitsiyenti|NKGN - Biznesning o‘zini qoplash muddati|NRBO (NeuroBo) - P/E multiplikatori|Narx-foyda koeffitsiyenti Sage Therapeutics Inc (SAGE)|P/E multiplikatori SNPX|Narxning foydaga nisbati TRVN (trevena.com)|Narxning foydaga nisbati Vigil Neuroscience, Inc. VIGL|anewmeds.com - Narxning foydaga nisbati|CERE - Narxning foydaga nisbati
